These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 2043882

  • 1. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
    Abraham VS, Sykes M.
    Bone Marrow Transplant; 1991; 7 Suppl 1():29-32. PubMed ID: 2043882
    [Abstract] [Full Text] [Related]

  • 2. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M.
    Transplantation; 1994 Dec 27; 58(12):1385-93. PubMed ID: 7809932
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M, Bukhari Z, Sachs DH.
    Bone Marrow Transplant; 1989 Sep 27; 4(5):465-74. PubMed ID: 2790325
    [Abstract] [Full Text] [Related]

  • 4. Alloengraftment in IL-2-treated mice.
    Sykes M, Pearson DA.
    Bone Marrow Transplant; 1992 Aug 27; 10(2):157-63. PubMed ID: 1525605
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M, Abraham VS, Harty MW, Pearson DA.
    J Immunol; 1993 Jan 01; 150(1):197-205. PubMed ID: 8093257
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Jan 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS, Sachs DH, Sykes M.
    J Immunol; 1992 Jun 15; 148(12):3746-52. PubMed ID: 1534824
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 17. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Sep 01; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 18. Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
    Stark J, Weiss L, Slavin S.
    Isr J Med Sci; 1992 Nov 01; 28(11):767-72. PubMed ID: 1468887
    [Abstract] [Full Text] [Related]

  • 19. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 01; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.